InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR.
Ratings
0 / 5
0 ratings in the last 12 months
5
4
3
2
1
CEO
Professor Niels Riedemann$76.3M
Market Cap • 06/05/20242007
(há 17 anos)
2017
(7 years ago)
NASDAQ
Listagem
Jena
48
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
IFRXSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.